The Facts About COVID-19 Delta Breakthrough Infection and Vaccine Bo…

Cleveland Clinic Rheumatology and Immunology Series

L. Calabrese

How the Pandemic Will Likely End for the Immunosuppressed and How to…

Cleveland Clinic Rheumatology and Immunology Series

L. Calabrese

COVID-19 & CDC Mask Guidance: Do Fully Vaccinated People Need to Wea…

RheumNow

J. Cush

COVID-19 and RMDs (February Update): The Role of Hyperinflammatory M…

Keck School of Medicine of USC

D. Arkfeld

Outcomes of COVID-19 Infection in Patients With Primary Systemic Vas…

ACR Convergence 2021 Coverage

S. Sattui Cortes

COVID-19 Hyper-Inflammation: Rheumatologic DMARD/Biologic Use

ACR Convergence 2021 Coverage

R. Q. Cron

Interleukin-6

Yale School of Medicine

R. Bucala

GI Side Effects of IL-17 Inhibitors, Downstream Revenues from Rheuma…

RheumNow

J. Cush

Epidemic Long COVID-19: Questions and Implications for Rheumatology

University Hospitals

L. Calabrese

Vaccines in Immunocompromised Patients

University Hospitals

N. Singer

Breakthrough Infections and Predicting Moderate-to-Severe COVID Outc…

Yuzaiful Yusof

COVID-19 and Rheumatic Diseases

Yale School of Medicine

V. Chowdhary

Rheumatic Disease & COVID-19 Vaccination: Why 55+ y/o Population Has…

RheumNow

J. Cush

Vaccine Responses in Immune-Mediated Inflammatory Diseases: Challeng…

Cleveland Clinic Rheumatology

A. Kim

Through the Lens of COVID-19: How We Recognize and Defend Ourselves …

Cleveland Clinic Rheumatology

L. Calabrese

October 2021 Update on FDA Approvals, News and the Latest Journal Ar…

John J. Cush

Best of EULAR 2021: RheumNow Conference Highlights

RheumNow

J. Cush

Updates on Tofacitinib Safety & COVID-19: What Are the New Tofacitin…

RheumNow

J. Cush

The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know …

The Journal of Rheumatology

E. Silverman, J. B. Galloway

Principles of Managing COVID-19 in High Risk Outpatients

Cleveland Clinic Rheumatology

C. Calabrese